Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation (ADPT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ADPT · as of Sep 30, 2025
Ownership Breakdown
273
Institutional Holders
▲ 28 vs Q2
$2.18B
Total Inst. Value
▲ $449.15M vs Q2
160.04M
Shares Outstanding
freeFloat 96.51%
145.42M
13F Shares Held
▼ 2.73M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ADPT largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VIKING GLOBAL INVESTORS LP biological products, (no diagnostic substances) | 29.99M | 19.72% | 19.72% | $448.71B | Nov 14, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 13.36M | 8.78% | 8.78% | $199.84B | Nov 12, 2025 | ▼ 308.9K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 11.28M | 7.41% | 7.41% | $168.68B | Nov 7, 2025 | ▼ 4.0K |
AMERIPRISE FINANCIAL INC biological products, (no diagnostic substances) | 5.97M | 3.93% | 3.93% | $89.34B | Nov 14, 2025 | ▲ 2.73M |
NIKKO ASSET MANAGEMENT AMERICAS, INC. biological products, (no diagnostic substances) | 3.65M | 2.40% | 2.40% | $54.65B | Nov 12, 2025 | ▼ 649.0K |
SUMITOMO MITSUI TRUST HOLDINGS, INC. biological products, (no diagnostic substances) | 3.65M | 2.40% | 2.40% | $54.61B | Oct 27, 2025 | ▼ 649.0K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 3.40M | 2.24% | 2.24% | $50.89B | Nov 12, 2025 | ▲ 185.9K |
ARK INVESTMENT MANAGEMENT LLC biological products, (no diagnostic substances) | 3.17M | 2.08% | 2.08% | $47.36B | Nov 12, 2025 | ▼ 850.8K |
ARISTOTLE ATLANTIC PARTNERS, LLC biological products, (no diagnostic substances) | 3.13M | 2.06% | 2.06% | $46.78B | Nov 14, 2025 | ▲ 247.4K |
STATE STREET CORP biological products, (no diagnostic substances) | 3.08M | 2.02% | 2.02% | $46.07B | Nov 14, 2025 | ▲ 52.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
21
Increased
+13.13M shares2
New Positions
first time holders25
Decreased
−8.93M shares0
Sold Out
fully exitedNet shares change (top 50)
+4.20M
+13.13M / −8.93M
Net new holders
-2
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ADPT insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
22
Buy transactions
49
Sell transactions
0.45
Buy/Sell ratio
$1M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
PISKEL KYLE Chief Financial Officer | May 18, 2026 | Sale | 3,115 | $13.04 | $40.6K | 256.7K | Form 4 ↗ |
RUBINSTEIN JULIE President and COO | Apr 27, 2026 | Sale | 19,037 | $14.23 | $270.9K | 377.8K | Form 4 ↗ |
RUBINSTEIN JULIE President and COO | Apr 22, 2026 | Sale | 19,060 | $14.13 | $269.3K | 390.8K | Form 4 ↗ |
RUBINSTEIN JULIE President and COO | Apr 23, 2026 | Sale | 19,060 | $13.74 | $261.9K | 386.5K | Form 4 ↗ |
RUBINSTEIN JULIE President and COO | Apr 24, 2026 | Sale | 19,060 | $14.02 | $267.2K | 382.1K | Form 4 ↗ |
RUBINSTEIN JULIE President and COO | Apr 17, 2026 | Sale | 19,060 | $14.57 | $277.7K | 403.8K | Form 4 ↗ |
RUBINSTEIN JULIE President and COO | Apr 20, 2026 | Sale | 19,060 | $14.55 | $277.3K | 399.5K | Form 4 ↗ |
RUBINSTEIN JULIE President and COO | Apr 21, 2026 | Sale | 30,941 | $14.66 | $453.6K | 395.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Adaptive Biotechnologies Corporation (ADPT) is primarily owned by institutional investors, who hold approximately 90.9% of total shares outstanding. Company insiders own approximately 3.49%, while retail and public investors account for the remaining 5.65%.
The largest institutional shareholder of Adaptive Biotechnologies Corporation is VIKING GLOBAL INVESTORS LP, holding approximately 29.99 million shares — equal to 19.72% of outstanding shares — as of September 30, 2025.
A total of 273 institutional investors currently hold ADPT stock, with a combined institutional value of approximately $2.18 billion as of the most recent 13F filing period.
Frequently asked questions
ADPT ownershipAdaptive Biotechnologies Corporation (ADPT) is primarily owned by institutional investors, who hold approximately 90.9% of shares. The largest shareholder is VIKING GLOBAL INVESTORS LP with a 19.72% stake. Company insiders hold 3.49%. Data sourced from SEC Form 13F as of September 30, 2025.